Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
NCT00994214
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
109
Enrollment
INDUSTRY
Sponsor class
Stopped
Preliminary data from this study does not support expected inhibition of GH and IGF-1
Conditions
Acromegaly
Interventions
DRUG:
BIM 23A760
Sponsor
Ipsen